Navigation Links
Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
Date:8/8/2013

LAWRENCEVILLE, N.J., Aug. 8, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2013 and an update from its retrospective analysis of the clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer (the DIGNITY Study).

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company has conducted a comprehensive analysis of the data from the Study supported by its key principal investigators as well as liver cancer and clinical data experts. The Company continues to follow patients enrolled in the HEAT Study to the secondary endpoint, Overall Survival (OS). 

As of the June 30, 2013 cut off, the date of the latest OS patient follow-up,  Celsion reports the following:

  • Overall Survival has not yet reached the median for the full HEAT Study population.  A total of 226 deaths have been recorded through June 30, 2013.
  • Subgroup analysis based on RFA heating duration continues to suggest that ThermoDox® markedly improves Overall Survival, when compared to the control group, in patients if their lesions undergo RFA for 45 minutes or more.  These findings apply to single HCC lesions (63% of the HEAT Study population) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent approximately 300 patients. '/>"/>

  • SOURCE Celsion Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
    2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
    3. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
    4. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
    5. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
    6. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
    7. Psychemedics Corporation Announces Top Revenue Quarter
    8. Comprehensive Care Corporation Signs Agreement With A National Leader In Pharmacy Benefit Management
    9. Luminex Corporation Reports Second Quarter 2013 Results
    10. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
    11. MGC Diagnostics Corporation to Present at the Southern California Investor Conference on Thursday, August 8, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
    (Date:10/22/2014)... VIEW, Calif. , Oct. 22, 2014 ... a.m. EDTLOCATION: Online, complimentary registration available at: ... Team Leader Archana Vidyasekar and Visionary Innovation ... computers, WiFi-like wireless electricity, self-assembling materials, nanobots ... ten technologies which will transform our lives ...
    (Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
    Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
    ... (NYSE: VAR ) will showcase radiosurgery technologies ... non-invasively at the 2012 International Conference of the American ... "We,re excited about putting our technology ... with radiosurgery as a treatment option for early-stage, inoperable ...
    ... 2012 OrbusNeich today announced that two subgroup ... of the company,s Combo Dual Therapy Stent versus ... with the Combo Stent.  Presented at EuroPCR 2012, ... tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at ...
    Cached Medicine Technology:Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 2Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 3Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 4
    (Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
    (Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
    (Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
    (Date:10/22/2014)... Salamon HealthDay Reporter , TUESDAY, ... vitro fertilization (IVF) are only about half as likely as ... technique, new research indicates, and the racial disparity persists even ... 31 percent of white patients became pregnant after IVF, compared ... than 4,000 IVF cycles over two years to tease out ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
    Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
    ... Researchers at the University of Pennsylvania School of ... associated with familial Alzheimer,s disease disrupt the flow ... called PS1 and PS2 (presenilin 1 and 2), ... intracellular cell compartment. , "The ,calcium dysregulation, hypothesis ...
    ... Without immediate action to develop an integrated, comprehensive, national health ... status as the global health care leader, states a new ... www.aahcdc.org ). The report was funded in part ... Out of Time: The State of the Nation,s Health Workforce ...
    ... cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, ... be working well to reduce tumors or hold them ... the result when this occurs is all too familiar: ... cancers become resistant. , A team of researchers at ...
    ... Baxa Corporation, a,Denver-based manufacturer of medical devices and ... the release,of a newly designed Web site for ... The online forum, known as eBUG for,electronic Baxa ... along,with creating a virtual ,community, for sharing pharmacy ...
    ... SIOUX FALLS, S.D., July 18 William S.,Harris, ... letter,dated July 16:, Eating fish, especially oily ... heart disease prevention. Fish is low in total ... minerals, and contains,long-chain omega-3 fatty acids (EPA and ...
    ... YORK, July 18 Standing Tall announced today ... Board of Directors., "Standing Tall has created ... the most severely disabled children in New York ... gain mobility and independence,by actively using their bodies ...
    Cached Medicine News:Health News:Calcium may be the key to understanding Alzheimer's disease 2Health News:Calcium may be the key to understanding Alzheimer's disease 3Health News:New report warns current policies will not avert health workforce crisis 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:Baxa Corporation Launches New Electronic Users' Group Web Site 2Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 2Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 3Health News:Bernadette Peters Joins Board of Directors of Standing Tall, Innovative Program for Multiply Disabled Children 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: